DOCSLIB.ORG

I Project Number

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
I Project Number Project Number: DTZ 1103 An Interactive Qualifying Project Report: Submitted to the Faculty of WORCESTER POLYTECHNIC INSTITUTE in partial fulfillment of the requirements for the Degree of Bachelor of Science By Joshua Nitso _____________________________ Kevin Woods _____________________________ Submitted April 23, 2012 Approved by Professor Dalin Tang, Project Advisor _____________________________________________ I ABSTRACT The history of the stock market and selected companies within the pharmaceutical industry were studied using the Internet and Gordon Library as primary resources. An eight-week simulation was conducted on the stock market using different trading techniques that were analyzed and compared for effectiveness. Using these strategies helped develop a basic understanding of the investing world and the relative success of different investment methods. II TABLE OF CONTENTS ABSTRACT .................................................................................................................................... II TABLE OF CONTENTS .............................................................................................................. III TABLE OF FIGURES ....................................................................................................................V TABLE OF TABLES .................................................................................................................. VII 1. INTRODUCTION ...................................................................................................................... 1 1.1 GOALS AND OBJECTIVES ............................................................................................... 2 1.2 GENERAL PLAN ................................................................................................................. 3 1.3 MARKET ANALYSIS ......................................................................................................... 4 1.3.1 FUNDAMENTAL ANALYSIS ..................................................................................... 4 1.3.2 TECHNICAL ANALYSIS ............................................................................................. 4 1.4 HISTORY OF STOCKS AND FINACIAL TRADING ....................................................... 5 1.4.1 BEGININGS HISTORY OF THE NYSE ...................................................................... 5 1.4.2 INDUSTRIAL AGE ....................................................................................................... 6 1.4.3 ELECTRONIC AGE ...................................................................................................... 7 1.4.4 TODAY .......................................................................................................................... 8 2. STRATEGIES........................................................................................................................... 10 2.1 DAY TRADING ................................................................................................................. 10 2.2 SHORT-TERM SWING TRADING .................................................................................. 11 2.2.1 TREND FOLLOWING ................................................................................................ 11 2.2.2 COUNTERTREND ...................................................................................................... 12 2.3 POSITION TRADING ........................................................................................................ 12 2.4 CAN SLIM .......................................................................................................................... 13 3. COMMON TOOLS .................................................................................................................. 14 3.1 MOVING AVERAGES ...................................................................................................... 14 3.1.1 SIMPLE MOVING AVERAGE .................................................................................. 15 3.1.2 EXPONENTIAL MOVING AVERAGE ..................................................................... 15 3.2 MACD ................................................................................................................................. 16 3.3 STOCHASTIC OSCILLATORS ........................................................................................ 17 4. HISTORY OF AMERICAN PHARMACEUTACAL INDUSTRY ........................................ 19 4.1 PRE-WORLD WAR I ......................................................................................................... 19 4.2 WORLD WAR .................................................................................................................... 19 4.3 WORLD WAR II ................................................................................................................ 20 4.4 1970’S – TODAY ............................................................................................................... 21 5. COMPANY HISTORIES FOR LONG-TERM INVESTMENTS ........................................... 22 5.1 PFIZER INCORPORATED (PFE) ..................................................................................... 22 5.2 MERCK & COMPANY INCORPORATED (MRK) ......................................................... 23 5.3 JOHNSON & JOHNSON (JNJ) .......................................................................................... 24 5.4 ELI LILLY AND COMPANY (LLY) ................................................................................ 26 5.5 BAXTER INTERNATIONAL INCORPORATED (BAX) ............................................... 27 6. SIMULATION 1: LONG-TERM INVESTMENTS ................................................................ 29 6.2 WEEK 1 (FEB. 7 – FEB. 12) .............................................................................................. 29 6.1.1 MONEY MARKET ACCOUNT ................................................................................. 29 6.1.2 BIG TICKET INDEX ................................................................................................... 30 6.1.3 MUTUAL FUNDS ....................................................................................................... 30 III 6.2 WEEK 2 (FEB. 13 – FEB. 19) ............................................................................................ 31 6.3 WEEK 3 (FEB.20 – FEB. 26) ............................................................................................. 32 6.4 WEEKS 4-6 (FEB. 27 – MAR.18) ...................................................................................... 33 6.5 WEEK 7 (MAR 19.-MAR.25) ............................................................................................ 34 6.6 WEEK 8 (MAR 26 – APR.1) .............................................................................................. 35 6.7 RESULTS AND DISCUSSION ......................................................................................... 36 7. SIMULATION 2: COUNTERTRENDING ............................................................................. 39 7.1 WEEK 1 (FEB. 7 – FEB. 12) .............................................................................................. 39 7.2 WEEK 2 (FEB. 13 –FEB. 19) ............................................................................................. 47 7.3 WEEK 3 (FEB. 20 – FEB 26) ............................................................................................. 52 7.4 WEEK 4-6 (FEB. 27 – MAR. 18) ....................................................................................... 56 7.5 WEEK 7 (MAR. 19 – MAR. 25) ........................................................................................ 59 7.6 WEEK 8 (MAR. 26 – APR. 1) ............................................................................................ 62 7.7 RESULTS AND DISCUSSION ......................................................................................... 64 8. SIMULATION 3: TREND FOLLOWING .............................................................................. 67 8.1 WEEK 1 (FEB. 7 – FEB.12) ............................................................................................... 67 8.2 WEEK 2 (FEB. 13 – FEB. 19) ............................................................................................ 75 8.3 WEEK 3 (FEB. 20 – FEB 26) ............................................................................................. 84 8.4 WEEKS 4-6 (FEB. 27 – MAR.18) ...................................................................................... 89 8.5 WEEK 7 (MAR.19 – MAR.25) .......................................................................................... 92 8.6 WEEK 8 (MAR.26 – APR. 1) ............................................................................................. 93 8.7 RESULTS AND DISCUSSION ......................................................................................... 96 9. CONCLUSIONS..................................................................................................................... 102 9.1 FINAL COMPARISON OF STRATEGIES ..................................................................... 102 9.2 WHAT WE LEARNED .................................................................................................... 107 REFERENCES ........................................................................................................................... 108 IV TABLE OF FIGURES* Figure 3.01: ABT, Weekly 1-Year
Load more

Recommended publications
  • Benadryl Allergy Relief Plus Decongestant Capsules
    Distance between cutted line/middel of the spot = 51.6 mm spot = 12 x 2 centered in the margin of 14 mm le f 14 mm GB Benadryl Allergy Relief Plus Decon Caps 12s PIL MAH Update CRD 6738 t margin 23.06.2021 English 402428175_r0 N/A 1 Brochure/Leaet/Insert 145 x 250 mm Capsules are a medicine which are used to blood pressure). 364350C IM_Val-de-Reuil_Upper Normandy_France relieve the symptoms of hay fever and similar ■ If you have glaucoma (increased pressure allergic conditions. The capsules contain in the eye). CTE LITE 364350B Westrock Saint Pierre des Corps pseudoephedrine hydrochloride, which is a ■ If you have an overactive thyroid gland. 845 Oset Printing decongestant that relieves nasal and sinus ■ If you have severe kidney problems. 7996903 PAPER congestion and acrivastine which is an ■ If you are taking, or have taken in the last EMEA_2021_00024796_003 PC-0002778 antihistamine that helps relieve allergy two weeks, drugs for depression known symptoms such as sneezing, runny nose and as Monoamine Oxidase Inhibitors CAPSULES watery eyes. (MAOIs) or Reverse Inhibitors of Acrivastine 8mg & Pseudoephedrine 60mg Monoamine Oxidase 2 Before taking this (RIMAs). ■ This medicine is used to relieve the symptoms ■ If you are taking any cough or of hay fever and similar allergic conditions. cold medicines. PANTONE PANTONE medicine 356 C 287 C ■ This medicine is for use by adults and If any of these apply to you, get advice from children aged 12 - 65 years. This medicine is suitable for most adults under LITHO OFFSET LITHO OFFSET 65 years old and children aged 12 years and a doctor or pharmacist without taking ■ Do not take this medicine: REPRESENTATION: Colours represented with a diagonal line have been modified to aid PDF approval.
    [Show full text]
  • Vers Un Modèle D'entreprise Hybride: L'évolution De La Gestion D'un Contexte De Loyauté Réciproque Vers Un Modèle De Marchés; Étude Du Cas De Johnson & Johnson
    UNIVERSITÉ DU QUÉBEC À MONTRÉAL VERS UN MODÈLE D'ENTREPRISE HYBRIDE: L'ÉVOLUTION DE LA GESTION D'UN CONTEXTE DE LOYAUTÉ RÉCIPROQUE VERS UN MODÈLE DE MARCHÉS; ÉTUDE DU CAS DE JOHNSON & JOHNSON MÉMOIRE PRÉSENTÉ COMME EXIGENCE PARTIELLE DELA MAÎTRISE EN ADMINISTRATION DES AFFAIRES (MBA-RECHERCHE) PAR FRÉDÉRIC TREMBLAY Novembre 2008 UNIVERSITÉ DU QUÉBEC À MONTRÉAL Service des bibliothèques Avertissement La diffusion de ce mémoire se fait dans le respect des droits de son auteur, qui a signé le formulaire Autorisation de reproduire et de diffuser un travail de recherche de cycles supérieurs (SDU-522 - Rév.01-2006). Cette autorisation stipule que «conformément à l'article 11 du Règlement no 8 des études de cycles supérieurs, [l'auteur] concède à l'Université du Québec à Montréal une licence non exclusive d'utilisation et de publication de la totalité ou d'une partie importante de [son] travail de recherche pour des fins pédagogiques et non commerciales. Plus précisément, [l'auteur] autorise l'Université du Québec à Montréal à reproduire, diffuser, prêter, distribuer ou vendre des copies de [son] travail de recherche à des fins non commerciales sur quelque support que ce soit, y compris l'Internet. Cette licence et cette autorisation n'entraînent pas une renonciation de [la] part [de l'auteur] à [ses] droits moraux ni à [ses] droits de propriété intellectuelle. Sauf entente contraire, [l'auteur] conserve la liberté de diffuser et de commercialiser ou non ce travail dont [il] possède un exemplaire.» REMERCIEMENTS La réalisation d'un mémoire de maîtrise est un travail exigeant, mais très formateur. Il pousse au dépassement de soi et à la réalisation de rêves autrefois formulés.
    [Show full text]
  • Over-The-Counter (OTC) Medications Applies To: Tufts Health Ritogether and Tufts Health Together*
    Over-the-Counter (OTC) Medications Applies to: Tufts Health RITogether and Tufts Health Together* As communicated in the November 1, 2018 Provider Update, the following changes are effective for fill dates on or after January 1, 2019. As a result of this change, some OTC medications will require prior authorization in certain circumstances as outlined below: Brand-Name OTC Medication Has a Covered Interchangeable Generic Version Available Afrin No Drip Advil capsule Advil tablet Advil PM tablet Afrin Nasal Spray Original nasal solution Afrin No Drip Aveeno Oatmeal Severe nasal Aleve tablet Baciguent ointment Benadryl capsule Bath Pak Treatment solution Benadryl Allergy Benadryl Allergy Benadryl Allergy Benadryl Extra Benefiber powder tablet capsule Liquid Strength cream Caltrate 600 +D Centrum Silver Betadine Swabstick Caltrate + D tablet Centrum liquid Plus Minerals tablet tablet Centrum Silver Centrum Ultra Men’s Children’s Advil Centrum tablet Cheracol-D syrup Adult 50+ tablet tablet suspension Children’s Benadryl Citracal Calcium + Children’s Benadryl Children’s Tylenol Chlor-Trimeton Allergy chewable D Slow Release Allergy liquid suspension syrup tablet tablet Citrucel Fiber Claritin-D 12 hour Claritin-D 24 hour Clear Cough Liquid Citrucel tablet Laxative powder tablet tablet PM Dimetapp DM Dex4 Fast Acting Dimetapp Cold and Colace capsule Conceptrol 4% gel Cough and Cold Glucose liquid Allergy elixir elixir Dristan nasal spray Dulcolax tablet D-Vi-Sol liquid Ecotrin tablet Evac powder Ex-Lax chewable Gas-X chewable Feosol tablet
    [Show full text]
  • 137814.Pdf (857.3Kb)
    UNIVERSIDAD PANAMERICANA FACULTAD DE FILOSOFÍA Y CIENCIAS SOCIALES ESCUELA DE PEDAGOGÍA HR Redesing C A S O Q U E P R E S E N T A ALEXIS TANIA CORELLA RAMÍREZ P A R A O B T E N E R E L G R A D O D E : MAESTRA EN CAPITAL HUMANO DIRECTOR DE LA TESIS: Dr. DAVID RENE THIERRY GARCÍA MÉXICO, D.F. 17 DE DICIEMBRE DEL 2012 Universidad Panamericana 2 HR Redesing Índice Introducción ....................................................................................................................................................... 3 Marco Contextual ............................................................................................................................................... 4 Historia de Johnson & Johnson ................................................................................................................... 4 Medical Devices & Diagnostics .................................................................................................................... 5 Global Surgery Group ................................................................................................................................. 5 Global Medical Solutions ............................................................................................................................. 6 Global Orthopaedics Group ......................................................................................................................... 6 Filosofía Institucional – Nuestro Credo .....................................................................................................
    [Show full text]
  • MEDICATIONS to AVOID PRIOR to ALLERGY SKIN TESTING Allergy
    MEDICATIONS TO AVOID PRIOR TO ALLERGY SKIN TESTING Allergy testing requires the ‘histamine response’ in order to be accurate and reliable. There are many types of antihistamines. Antihistamines are found in many different medicines, either as a single drug or mixed with a combination of chemicals. Please review all medicines you take (including Over-The-Counter) in order to make your allergy testing appointment most efficient and accurate. Generic names are in all lower case, trade names Capitalized. Oral antihistamines to be stopped 3 (THREE) days prior to your appointment: - brompheniramine (Actifed, Atrohist, Dimetapp, Drixoral) - cetirizine (Zyrtec, Zyrtec D) - chlopheniramine (Chlortrimeton, Deconamine, Kronofed A, Novafed A, Rynatan, Tussinex) - clemastine (Tavist, Antihist) - cyproheptadine (Periactin) - diphenhydramine (Benadryl, Allernix, Nytol) - doxylamine (Bendectin, Nyquil) - hydroxyzine (Atarax, Marax, Vistaril) - levocetirizine (Xyzal) - promethazine (Phenergan) Oral antihistamines to be stopped 7 (SEVEN) days prior to your appointment: - desloratadine (Clarinex) - fexofenadine (Allegra, Allegra D) - loratadine (Claritin, Claritin D, Alavert) Nose spray and eye drop antihistamines to stop 5 (FIVE) days prior to your appointment: - azelastine (Astelin, Astepro, Dymista, Optivar) - bepotastine (Bepreve) - ketotifen (Zaditor, Alaway) - olapatadine (Pataday, Patanase) - pheniramine (Visine A, Naphcon A) – OK to stop for 2 days Antacid medications (different type of antihistamine) to stop 3 (THREE) days prior to your appointment: - cimetidine (Tagamet) - famotidine (Pepcid) - ranitidine (Zantac) Note: Antihistamines are found in many over the counter medications, including Tylenol Allergy, Actifed Cold and Allergy, Alka-Seltzer Plus Cold with Cough Formula, and many others. Make sure you read and check the ingredients carefully and stop those containing antihistamines at least 3 (THREE) days prior to the appointment.
    [Show full text]
  • Lna 2006 Profiles J.Qxp
    1 | Advertising Age | June 26, 2006 SpecialSpecial ReportReport:100 Profiles LEADING NATIONAL ADVERTISERSSupplement SUPPLEMENT June 26, 2006 100 LEADING NATIONAL ADVERTISERS Profiles of the top 100 U.S. marketers in this 51st annual ranking INSIDE TOP 100 RANKING COMPANY PROFILES SPONSORED BY The nation’s leading marketers Lead marketing personnel, ranked by U.S. advertising brands, agencies, agency expenditures for 2005. contacts, as well as advertising Includes data from TNS Media spending by media and brand, Intelligence and Ad Age’s sales, earnings and more for proprietary estimates of the country’s 100 largest unmeasured spending. PAGE 8 advertisers PAGE 10 This document, and information contained therein, is the copyrighted property of Crain Communications Inc. and The Ad Age Group (© Copyright 2006) and is for your personal, non-commercial use only. You may not reproduce, display on a website, distribute, sell or republish this document, or information contained therein, without prior written consent of The Ad Age Group. Are proud to connect you with the leading CMOs See all the interviews at adage.com/point LAUNCHING JUNE 28 © 2006 Crain Communications Inc. www.adage.com 3 | Advertising Age | June 26, 2006 Special Report 100 LEADING NATIONAL ADVERTISERS SUPPLEMENT ABOUT THIS PROFILE EDITION THE 51ST ANNUAL 100 Leading National the Top 100 ($40.13 billion) and for all measured spending in 18 national media, Advertisers Report crowned acquisition- advertisers ($122.79 billion) in the U.S. Yellow Pages Association contributed ladened Procter & Gamble Co. as the top U.S. ad spending by ad category: This spending in Yellow Pages and TNS Marx leader, passing previous kingpen General chart (Page 6) breaks out 18 measured Promotion Intelligence provided free- Motors Corp.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Caring for the World . . .One Person at a Time™ Inspires and Unites the People of Johnson & Johnson
    OUR CARING TRANSFORMS 2007 Annual Report Caring for the world . .one person at a time™ inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. The people in our more than 250 companies come to work each day inspired by their personal knowledge that their caring transforms people’s lives . one person at a time. On the following pages, we invite you to see for yourself. Our Caring Transforms ON THE COVER Johnson & Johnson is founding sponsor and continues to support Safe Kids Worldwide®. For 20 years the organization has grown, now teaching prevention as a way to save children’s lives in 17 countries around the world. In Brazil, Nayra Yara da Paz de Jesus carefully washes her hands, a safe, healthy habit she and other children are learning from a local Safe Kids® program. Find out more in our story on page 22. C H A I R M A N ’ S L E T T E R To Our Shareholders Caring for the health and well-being of people throughout the world is an extraordinary business. It is a business where people are passionate about their work, because it matters. It matters to their families, to their communities and to the world. It is a business filled with tremendous opportunity for leadership and growth in the 21st century; a business where unmet needs still abound and where people around the world WILLIAM C.
    [Show full text]
  • Preparation for Your First Visit and Allergy Testing
    PREPARATION FOR YOUR FIRST VISIT AND ALLERGY TESTING Please allow up to 2 hours for your skin test appointment. In order to obtain valid and useful skin testing results, you need to discontinue the use of certain medications for a specific time before the skin test and your appointment. 1. All sleep aids and over the counter medications must be withheld for 2 to 5 days before your appointment. 2. Because most cough preparations contain antihistamines, these must be withheld for 2 days. 3. Prescription nose sprays like Nasonex, Nasacort AQ, Rhinocort AQ, Flonase, Nasarel, Beconase and Singulair Tablets DO NOT interfere with testing. You do not need to stop them before your appointment. 4. Asthma inhalers (inhaled corticosteroids) do not need to be discontinued. 5. Asthma medications such as theophylline and Singulair (montelukast) do not need to be discontinued. 6. If you are pregnant or suspect you may be pregnant please notify our staff immediately. You are not eligible for allergy skin testing at anytime during pregnancy. Blood testing for allergens is recommended during pregnancy. 7. Please allow a minimum of 2 hours for allergy testing. Feel free to bring reading materials, an iPod, handheld games or some other type of activity to entertain you during the test. 8. We respectfully request that our patients refrain from wearing perfumes and/or colognes which may harm those individuals with respiratory problems. 9. If you are taking medication with antihistamine effects which cannot be stopped because of the severity of your condition or any other reason, continue taking the medication and let the clinic know at your initial visit.
    [Show full text]
  • MHS) Is Committed to Providing Appropriate, High-Quality, and Cost- Effective Drug Therapy to All MHS Members
    Pharmacy Program Managed Health Services (MHS) is committed to providing appropriate, high-quality, and cost- effective drug therapy to all MHS members. MHS works with providers and pharmacists to ensure that medications used to treat a variety of conditions and diseases are covered. MHS covers prescription medications and certain over-the-counter (OTC) medications when ordered by an Indiana Medicaid enrolled MHS practitioner. The pharmacy program does not cover all medications. Some medications require prior authorization (PA) or have limitations on age, dosage, and maximum quantities. For the most current information about the MHS Pharmacy Program you may call Member Services at 1-877-647-4848 (TTY/TTD 1-800-743-3333) or visit the MHS website at mhsindiana.com. Preferred Drug List The MHS Preferred Drug List (PDL) is the list of covered drugs. The PDL applies to drugs that members can receive at retail pharmacies. The MHS PDL is continually evaluated by the MHS Pharmacy and Therapeutics (P&T) Committee to promote the appropriate and cost-effective use of medications. The Committee is composed of the MHS Medical Director, MHS Pharmacy Director, and several Indiana physicians, pharmacists, and specialists. Pharmacy Benefit Manager Envolve Pharmacy Solutions (EPS) is our Pharmacy Benefit Manager. MHS works with EPS to process all pharmacy claims for prescribed drugs. Some drugs on the MHS PDL require PA, and EPS is responsible for administering this process. Specialty Drugs Certain medications are only covered when supplied by MHS’ specialty pharmacy provider. AcariaHealth is our specialty pharmacy provider. A medical provider can obtain specialty medications through Acaria Health.
    [Show full text]
  • 2016 Annual Report
    ANNUAL REPORT 2016 MARCH 2017 TO OUR SHAREHOLDERS ALEX GORSKY Chairman and Chief Executive Officer I’ve worked in the health care industry for Rather, true innovations are the result of WE ARE UNITED nearly 30 years. It’s been both an honor and collaboration. And that collaboration is AND INSPIRED a privilege to work for Johnson & Johnson, driven by a diversity of ideas, individuals BY OUR CREDO, a company that touches the lives of over and disciplines – working together toward WHICH RINGS a billion people every day, around the a common goal. AS TRUE TODAY world. As I look at today’s health care AS IT DID WHEN landscape, it’s incredibly clear that the Today, more than ever, the world needs IT WAS WRITTEN pace of change has never been greater, leaders who are committed to working MORE THAN 70 or frankly, more exciting. together to help bring improved health YEARS AGO. and wellness to every person in every Today’s rapid change brings both corner of the globe. As the world’s largest opportunities and risks for any company and most broadly based health care in health care, and we are prepared company, we are uniquely positioned to help to address both. There are significant transform global health care; to shine a light challenges to overcome, but the tools, the on the most important issues we are facing; insights, the technologies, the innovations to collaborate across boundaries and – both evolutions and revolutions – all borders; to uncover scientific insights and combine to make today one of the most ideas; and to dedicate resources towards promising times for human health and for creating tomorrow’s breakthroughs.
    [Show full text]
  • 2017 Health for Humanity Report Progress in Citizenship & Sustainability 2017 Health for Humanity Report 2
    Executive Summary 2017 Health for Humanity Report Progress in Citizenship & Sustainability 2017 Health for Humanity Report 2 Message from Alex Gorsky It was created with the stroke of for you, our shareholders. It’s our way of a pen in 1886. demonstrating how we work to track and deliver on our commitments. James Wood Johnson, who co-founded the See, for example, how we’re eradicating and company with his brother Edward Mead preventing disease. Johnson, handcrafted one the world’s most trusted logos. James wanted the world to We’ve achieved great milestones as a know just how personally and emotionally company this year in our efforts to make connected the two were to the company’s HIV history with the initiation of the first most important reason for being—improving efficacy study for a preventative vaccine. I’m human health. So, he decided to use the encouraged every time I reflect on how far family signature. we’ve come since the 1980s with HIV, once considered a death sentence. All of us are Johnson & Johnson. humbled to be a part of the efforts to treat Placing their name on the company’s and protect—even, one day, prevent—HIV. products was the ultimate measure of I’m also proud of how we’re reimagining the accountability. It was a way of holding way that care is delivered and expanding themselves responsible for their—and their access for the world’s most vulnerable Alex and Pat Gorsky in Valmiki Basti, one of the oldest communities in New Delhi, India, where they visited the company’s—every action.
    [Show full text]